Centre for Obesity Research and Education, Monash University, The Alfred Hospital, Melbourne, Victoria, Australia.
J Gastroenterol Hepatol. 2010 Aug;25(8):1358-65. doi: 10.1111/j.1440-1746.2010.06391.x.
The rising problem of obesity is causing major health problems, reduced quality of life and reduced life expectancy. It now generates approximately 10% of all health costs. The progression of the problem indicates preventive measures have been unsuccessful so far. Only bariatric surgical treatments have been able to achieve substantial and durable weight loss. Gastric banding and gastric bypass are used in more than 90% of bariatric operations. The proportion of each varies from greater than 95% bands in Australia, about 50/50 in Europe and USA and nearly 100% bypass in South America. The availability of follow up is a prime determinant of choice. Understanding the mechanisms of effect for the bariatric procedures is central to optimizing their effect. The traditional narrow concepts of restrictive (blocking the transit of food) and malabsorptive (preventing the absorption of food) should be discarded and the importance of induction of satiety, change of taste, diversion of chyme, neural and hormonal mediation and the effects of aversion need to be included. The primary mechanism of effect for gastric banding is the generation of a background of satiety and early post-prandial satiation via specifically structured vagal afferents at the level of the band. At five years after banding or bypass, there is typically a loss of 30-35 kg representing 50-60% of excess weight. This weight loss has been shown to be associated with major improvement or complete resolution of multiple common and serious health problems plus improvement in quality of life and in survival. Level 1 evidence supports the use of the gastric band over optimal lifestyle therapy. Randomized controlled trials has shown gastric banding to achieve better weight loss, health and quality of life than optimal lifestyle therapies for adults above a BMI of 30 and adolescents above a BMI of 35. In adults with mild to severe obesity and type 2 diabetes gastric banding leads to remission in three out of four individuals. Perioperative risk is significant with gastric bypass and late revisional procedures can be required after both procedures. Gastric banding is indicated in any adult who has a BMI over 30, has problems with their obesity and has made substantial effort to reduce their weight by lifestyle methods. Gastric bypass or biliopancreatic diversion should be considered in those with BMI greater than 35 if banding is contraindicated or has been unsuccessful.
肥胖问题日益严重,导致严重的健康问题、生活质量下降和预期寿命缩短。它现在占所有医疗保健费用的约 10%。问题的发展表明迄今为止预防措施并不成功。只有减重手术才能实现实质性和持久的体重减轻。胃带和胃旁路术在超过 90%的减重手术中使用。每种方法的比例在澳大利亚大于 95%的带,欧洲和美国约为 50/50,南美洲几乎 100%的旁路。后续治疗的可获得性是选择的主要决定因素。了解减重手术的作用机制对于优化其效果至关重要。传统的限制性(阻止食物通过)和吸收不良(阻止食物吸收)狭窄概念应该被摒弃,应该包括饱腹感的诱导、味觉的改变、食糜的分流、神经和激素调节以及厌恶感的作用。胃带的主要作用机制是通过带水平的特定结构的迷走传入纤维产生背景性饱腹感和早期餐后饱腹感。在胃带或旁路手术后五年,通常会减轻 30-35 公斤,代表超重体重的 50-60%。已经证明这种体重减轻与多种常见和严重健康问题的显著改善或完全解决以及生活质量和生存的改善有关。一级证据支持使用胃带而不是最佳生活方式治疗。随机对照试验表明,与最佳生活方式治疗相比,胃带在成人 BMI 超过 30 和青少年 BMI 超过 35 时,能实现更好的减重、健康和生活质量。对于轻到重度肥胖和 2 型糖尿病患者,胃带能使四分之三的患者病情缓解。胃旁路术的围手术期风险较高,两种手术后都可能需要进行后期修正手术。任何 BMI 超过 30、肥胖问题严重且已通过生活方式方法努力减轻体重的成年人都适合进行胃带治疗。对于 BMI 大于 35 的患者,如果带不合适或不成功,应考虑胃旁路或胆胰分流术。
J Gastroenterol Hepatol. 2010-8
Bull Acad Natl Med. 2010-1
Postgrad Med. 2008-9-15
Nutrients. 2024-5-13
Int J Obes (Lond). 2024-6
Diabetes Metab Syndr Obes. 2024-1-3
J Community Hosp Intern Med Perspect. 2023-6-29